Azmasol® Bexicap capsule contains Salbutamol (as Salbutamol sulphate BP) as the active ingredient which is a β2 -adrenoceptor agonist used in the treatment of asthma and other forms of diffuse reversible airways obstruction. Azmasol® Bexicap (Salbutamol) dry powder inhaler is indicated for the treatment and prophylaxis of bronchial asthma and for the treatment of reversible airways obstruction associated with bronchitis and emphysema. Azmasol® Bexicap (Salbutamol) inhaler may be used to relieve attacks of acute dyspnoea and may also be taken prophylactically before exertion or to prevent exercise-induced asthma.
Bexitrol-F Bexicap is a Dry Powder inhaler (DPI) contains two medicines, Salmeterol Xinafoate BP and Fluticasone Propionate BP. Salmeterol Xinafoate is a selective, long acting b2 agonist acts as bronchodilator. Fluticasone Propionate is a corticosteroid with mainly glucocorticoid activity. It reduces swelling and irritation in the lungs. Bexitrol F is indicated in the regular treatment of asthma where use of a combination product (long acting b2 agonist and inhaled corticosteroid) is appropriate and in patient with severe Chronic Obstructive Pulmonary Disease (COPD). Bexitrol-F Bexicap is available as Innovative Patient friendly and DPI friendly packaging.
Formoterol is a very potent, long-acting, beta2 adrenoceptor-agonist with a high intrinsic activity and a rapid onset of action. Symbion® Bexicap capsule is a combination of Formoterol Fumarate Dihydrate and Budesonide. Budesonide is a potent glucocorticoid that binds with high affinity to the glucocorticoid receptor. It has a high ratio of topical to systemic activity.
Tioriva® Bexicap (Dry Powder Inhaler) capsule contains Tiotropium Bromide Monohydrate BP as the active ingredient which is a long-acting, antimuscarinic agent, which is often referred to as an anticholinergic. Tioriva® is indicated as maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Dosage